Nonmyeloablative allogeneic hematopoietic stem cell transplantation

Journal of Hematotherapy and Stem Cell Research

Volumn 11, Issue 2, 2002, Pages 243-263

  Baron, F ^a   Beguin, Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BUSULFAN; CD4 ANTIGEN; CD8 ANTIGEN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; HLA ANTIGEN; IMATINIB; INTERLEUKIN 2; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; RECOMBINANT INTERLEUKIN 2; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW APLASIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; LYMPHOMA; MORTALITY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SOLID TUMOR; ALLOTRANSPLANTATION; BLOOD DISEASE; HISTOCOMPATIBILITY; METHODOLOGY;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036223859     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581602753658448     Document Type: Review

References (183)

1. Treatment of murine leukaemia with X-rays and homologous bone marrow
2. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts
3. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation
4. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion
5. Graft-versus-leukemia in bone marrow transplantation
6. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
7. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes
8. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
9. The graft-versus-tumor potential of allogeneic cell therapy: An update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation
10. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
11. Adoptive immunotherapy: Insights from donor lymphocyte infusions
12. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation
13. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
14. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
15. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
16. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune response
17. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
18. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
19. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation
20. Non-myeloablative stem cell transplants
21. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
22. Nonmyeloablative preparative regimens: How relevant for acute myelogenous leukemia?
23. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone-marrow transplantation
24. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies
25. Graft-versus-leukemia reactions after bone marrow transplantation
26. T-cell depletion of HLA-identical transplants in leukemia
27. Evolving strategies to address adverse transplant outcomes associated with T cell depletion
28. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukemia following allogeneic bone marrow transplantation
29. Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome
30. Complete cytogenetic response with host-derived hematopoiesis induced by cyclosporin A discontinuation in a patient with relapsed chronic myelogenous leukemia after bone marrow transplantation
31. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: Single-center experience of 32 adult patients
32. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia
33. Adoptive immunotherapy with donor lymphocyte transfusions
34. Use of leukemic dendritic cells for the generation of antileukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome positive chronic myelogenous leukemia
35. Specific T cell therapy in Leukemia
36. Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation
37. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
38. Donor lymphocyte infusion for posttransplant relapse of Hodgkin's lymphoma
39. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
40. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma
41. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
42. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: Impact of infused and residual donor T cells
43. Chronic graft-versus-host disease
44. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
45. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
46. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
47. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
48. Adoptive immunotherapy with CD8-depleted donor lymphocytes (DLI) after CD34-selected peripheral blood stem cell (PBSC) transplantation
49. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions
50. Mechanisms of the graft-versus-leukemia reaction
51. Cytokine dysregulation and acute graft-versus-host disease
52. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effect by activated natural killer cells after allogeneic bone marrow transplantation
53. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
54. Cellular therapy of cancer with natural killer cells: Will it ever work?
55. Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease
56. The benefits of an alloresponse: Graft-versus-tumor
57. The biology of natural killer cells and implications for therapy of human disease
58. Donor lymphocyte infusions
59. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
60. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of donor hematopoiesis predicts aplasia
61. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for B-thalassemia major
62. Infusion of donor lymphocytes to eradicate recurrent host hematopoiesis after allogeneic bone marrow transplantation for sickle cell disease
63. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cell lines by cytotoxic T-cells clones
64. + minor histocompatibility antigen-specific cytotoxic T lymphocytes
65. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units
66. Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia
67. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
68. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WTI
69. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer
70. Graft-versus-tumor effect in non-small lung cancer after allogeneic peripheral blood stem cell transplantation
71. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
72. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
73. Graft-versus-tumor and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia
74. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft- versus -tumor effect
75. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood-stem-cell transplantation
76. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia
77. Bone-marrow transplantation
78. Autologous or allogeneic bone marrow transplantation compared intensive chemotherapy in acute myeloid leukemia
79. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the european group for blood and marrow transplantation
80. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study
81. A review of autologous hematopoietic cell transplantation
82. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
83. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase: A randomized trial of two irradiation regimens
84. Microenvironmental regulation of hematopoietic stem cells
85. Experimental culture conditions are critical for ex vivo expansion of hematopoietic cells
86. Nonmyeloablative transplants: Preclinical and clinical results
87. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation
88. Graft rejection and graft-versus-host disease in marrow transplantation
89. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients
90. Effect on T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia
91. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
92. Mixed chimerism: Preclinical studies and clinical applications
93. Mixed chimerism and transplant tolerance
94. Coexistence of two functioning T-cell repertoires in healthy ex-thalassemics bearing a persistent mixed chimerism years after bone marrow transplantation
95. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation
96. Bone marrow transplantation for sickle cell disease
97. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies
98. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft
99. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice
100. Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice
101. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems
102. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen
103. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat
104. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism
105. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease
106. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
107. Autologous haematopoietic stem cell transplants for autoimmune disease-feasibility and transplant-related mortality
108. Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation
109. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis
110. Minimal residual disease is more common in patients who have mixed cell chimerism after bone marrow transplantation for chronic myelogenous leukemia
111. Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: Is there an option to prevent relapse?
112. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia
113. Hematopoietic chimerism predicts relapse in T-cell depleted bone marrow transplantation followed by delayed T cell add-back
114. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting
115. Donor lymphocyte infusion postnon-myeloablative allogeneic peripheral blood stem cell transplantation for granulomatous disease
116. Molecular assessment of post-BMT chimerism using various biologic specimens and automated DNA sizing technology
117. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic bone marrow transplantation (BSCT) using multiplex PCR amplification of short tandem repeat markers
118. Acute leukemias
119. Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy
120. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias
121. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukemia and lymphoma
122. Allogeneic hematopoietic stem cell transplants after immune-ablative preparative regimen. A report of 92 cases
123. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin
124. Lymphohematopoietic graft-versus-host reactions can be induced without graft-versus-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen
125. Allogeneic transplantation for leukemia in patients older than 60 years: Age should not exclude treatment with non-myeloablative regimens
126. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy -induced marrow aplasia and progressive pulmonary aspergillosis
127. The importance of patient selection in non-myeloablative stem cell transplant (NMSCT) for acute and chronic leukaemia, myelodysplastic syndrome and myeloma
128. Molecular remissions after non-myeloablative allografting for chronic myelocytic leukemia (CML)
129. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice
130. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines
131. Protection from graft-versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow
132. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
133. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial
134. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF)
135. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
136. Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely effects progression free survival
137. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation
138. Favorable outcome of non-myeloablative stem cell transplant (NMSCT) for chronic myeloid leukaemia (CML) in first chronic phase: A retrospective study of the european group for blood and marrow transplantation (EBMT)
139. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
140. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience
141. Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease
142. Fludarabine-based non-myeloablative preparative regimen followed by allogeneic PBSC transplantation for solid tumors
143. Mini-allografts: Ongoing trials in humans
144. Non-myeloablative allogeneic stem cell transplantation as immunotherapy for metastatic melanoma: Results of a pilot study
145. The host-tumor immune conflict: From immunosuppression to resistance and destruction
146. How tumor escape immune destruction and what we can do about it
147. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation
148. Complexity of effector mechanisms in cyclosporine-induced syngeneic graft-versus-host disease
149. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation
150. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission
151. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia
152. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia
153. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation
154. CD8-depleted donor lymphocyte infusion (DLI) for the treatment of CML relapse after allogeneic transplant: Long-term follow-up and factors predicting outcome
155. Pathogenesis of acute graft-versus-host disease: Cytokines and cellular effectors
156. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell (PBSC) transplantation
157. Gene transfer applied to the modulation of alloreactivity
158. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
159. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir
160. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors
161. Primary T lymphocytes as targets for gene therapy
162. Phase I/II study of thymidine kinase (TK)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies
163. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
164. Cellular immunotherapy of EBV-associated lymphomas
165. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution
166. Feasibility of immunotherapy of relapsed leukemia with ex vivo generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
167. + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia
168. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients
169. Ex vivo cytokine activation of peripheral blood stem cells: A potential role for adoptive cellular immunotherapy
170. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation
171. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
172. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCL-ABL positive cells
173. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia
174. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
175. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome
176. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
177. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
178. Treatment of leukaemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571
179. STI-571 induces mixed chimerism in patients relapsing in blastic transformation after allogeneic stem cell transplantation for chronic myeloid leukemia
180. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients
181. Non-myeloablative allogeneic stem cell transplantation for the treatment of patients with chronic myeloid leukemia
182. Nonmyeloablative allogeneic stem cell transplantation with CD8-depleted or CD34-selected PBSC